Evotec (EVT) Panoramica del titolo
Evotec SE opera come partner per la scoperta e lo sviluppo di farmaci per l'industria farmaceutica e biotecnologica in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 4/6 |
| Dividendi | 0/6 |
EVT Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Evotec SE
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €4.62 |
| Massimo di 52 settimane | €8.57 |
| Minimo di 52 settimane | €4.00 |
| Beta | 1.3 |
| Variazione di 1 mese | -16.72% |
| Variazione a 3 mesi | -25.35% |
| Variazione di 1 anno | -35.83% |
| Variazione a 3 anni | -76.56% |
| Variazione a 5 anni | -87.08% |
| Variazione dall'IPO | -70.68% |
Notizie e aggiornamenti recenti
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.Recent updates
EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside
Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions
Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside
Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions
Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.
EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.EVT: Kidney Disease Milestone Prospects Will Support Future Upside
Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside
Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).EVT: Milestone Progress And Share Buybacks Will Support Future Upside
Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.EVT: Milestone Payment And Buyback Will Support Future Upside
Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside
Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.EVT: Share Buybacks And Milestone Payment Will Support Future Upside
Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.Large Pharma Partnerships And AI Platforms Will Open New Markets
The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
Pharmaceutical Collaborations And Cost Savings Will Drive Excellence
Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb
Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price
Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny
The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price
With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...Rendimenti per gli azionisti
| EVT | DE Life Sciences | DE Mercato | |
|---|---|---|---|
| 7D | -10.8% | -2.9% | -0.6% |
| 1Y | -35.8% | -18.9% | 0.2% |
Ritorno vs Industria: EVT ha avuto una performance inferiore rispetto al German Life Sciences che ha registrato un rendimento -18.9 % nell'ultimo anno.
Rendimento vs Mercato: EVT ha avuto una performance inferiore al mercato German che ha registrato un rendimento 0.2 % nell'ultimo anno.
Volatilità dei prezzi
| EVT volatility | |
|---|---|
| EVT Average Weekly Movement | 8.9% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.7% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di EVT è stato volatile rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di EVT è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1993 | 4,526 | Christian Wojczewski | www.evotec.com |
Evotec SE opera come partner per la scoperta e lo sviluppo di farmaci per l'industria farmaceutica e biotecnologica a livello mondiale. Opera in due segmenti, Shared R&D e Just Evotec Biologics. L'azienda sta sviluppando prodotti farmaceutici in diverse aree terapeutiche, quali oncologia, autoimmuni, cancro, diabete, insufficienza cardiaca, fibrosi, immunologia, dolore e infiammazione, malattie infettive, renali, epatiche, rare, respiratorie, fibrotiche e metaboliche; disordini del sistema nervoso centrale (SNC) e cardio metabolici; salute degli animali e delle donne.
Evotec SE Riepilogo dei fondamenti
| EVT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €835.42m |
| Utili (TTM) | -€193.88m |
| Ricavi(TTM) | €745.04m |
EVT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| EVT Conto economico (TTM) | |
|---|---|
| Ricavi | €745.04m |
| Costo del fatturato | €665.62m |
| Profitto lordo | €79.42m |
| Altre spese | €273.29m |
| Utili | -€193.88m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 13, 2026
| Utile per azione (EPS) | -1.09 |
| Margine lordo | 10.66% |
| Margine di profitto netto | -26.02% |
| Rapporto debito/patrimonio netto | 55.4% |
Come si è comportato EVT nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/15 19:06 |
| Prezzo dell'azione a fine giornata | 2026/05/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Evotec SE è coperta da 23 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Christian Ehmann | Berenberg |
| Michael Ryskin | BofA Global Research |
| Peter Verdult | Citigroup Inc |